Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0S5BV
|
||||
| Former ID |
DNCL001605
|
||||
| Drug Name |
ABT-652
|
||||
| Indication | Diabetic neuropathy; Musculoskeletal pain [ICD9: 250, 250.6, 356.0, 356.8, 338, 780; ICD10:E11.40, R52, G89] | Phase 2 | [1] | ||
| Company |
Abbott Laboratories
|
||||
| Target and Pathway | |||||
| Target(s) | Histamine H3 receptor | Target Info | Modulator | [2] | |
| KEGG Pathway | Neuroactive ligand-receptor interaction | ||||
| Reactome | Histamine receptors | ||||
| G alpha (i) signalling events | |||||
| WikiPathways | Monoamine Transport | ||||
| GPCRs, Class A Rhodopsin-like | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT01207115) A Study of ABT-652 in Adults With Osteoarthritis Pain of the Knee. U.S. National Institutes of Health. | ||||
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032225) | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.